Billionaire Laffont sold Nvidia and AMD, invested in Eli Lilly and Novo Nordisk in growing industry.

From Nasdaq: 2025-01-31 04:30:00

Philippe Laffont, founder of Coatue Management, manages $26.9 billion in investments, with a focus on innovative companies in the tech sector. In the third quarter, he reduced holdings in Nvidia and AMD while increasing positions in Eli Lilly and Novo Nordisk, companies dominating the weight loss drug market expected to reach $100-$130 billion by 2030.

Laffont’s confidence in Nvidia and AMD remains despite reducing positions. Nvidia leads in AI chip design with a 70% market share, while AMD shows significant growth in AI chip demand. Laffont increased investments in Eli Lilly and Novo Nordisk, anticipating significant growth in the weight loss drug market, which could reach over $100 billion by 2030.

Considering the potential for significant growth in the weight loss drug market, Laffont’s increased investments in Eli Lilly and Novo Nordisk could prove beneficial. Both companies have blockbuster drugs like Mounjaro, Zepbound, Ozempic, and Wegovy, showing promising results in managing blood sugar levels and appetite to aid weight loss, with Medicare approvals enhancing accessibility for patients.



Read more at Nasdaq: Billionaire Philippe Laffont Just Sold Top Artificial Intelligence Stocks Nvidia and AMD and Piled Into 2 Players Dominating Another High-Growth Billion-Dollar Industry